These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15470802)

  • 1. Serum levels of substance P and response to antidepressant pharmacotherapy.
    Lieb K; Walden J; Grunze H; Fiebich BL; Berger M; Normann C
    Pharmacopsychiatry; 2004 Sep; 37(5):238-9. PubMed ID: 15470802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substance P serum levels are increased in major depression: preliminary results.
    Bondy B; Baghai TC; Minov C; Schüle C; Schwarz MJ; Zwanzger P; Rupprecht R; Möller HJ
    Biol Psychiatry; 2003 Mar; 53(6):538-42. PubMed ID: 12644359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substance P in serum and cerebrospinal fluid of depressed patients: no effect of antidepressant treatment.
    Deuschle M; Sander P; Herpfer I; Fiebich BL; Heuser I; Lieb K
    Psychiatry Res; 2005 Jul; 136(1):1-6. PubMed ID: 16024091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
    Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
    J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability.
    Ivković M; Damjanović A; Jovanović A; Cvetić T; Jasović-Gasić M
    Psychiatr Danub; 2009 Jun; 21(2):187-93. PubMed ID: 19556947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained remission with lamotrigine augmentation or monotherapy in female resistant depressives with mixed cyclothymic-dysthymic temperament.
    Manning JS; Haykal RF; Connor PD; Cunningham PD; Jackson WC; Long S
    J Affect Disord; 2005 Feb; 84(2-3):259-66. PubMed ID: 15708424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine.
    van der Loos ML; Mulder P; Hartong EG; Blom MB; Vergouwen AC; van Noorden MS; Timmermans MA; Vieta E; Nolen WA;
    Acta Psychiatr Scand; 2010 Sep; 122(3):246-54. PubMed ID: 20136801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypomania induced by adjunctive lamotrigine.
    Margolese HC; Beauclair L; Szkrumelak N; Chouinard G
    Am J Psychiatry; 2003 Jan; 160(1):183-4. PubMed ID: 12505823
    [No Abstract]   [Full Text] [Related]  

  • 9. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
    Greist J; McNamara RK; Mallinckrodt CH; Rayamajhi JN; Raskin J
    Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive study.
    Gabriel A
    Depress Anxiety; 2006; 23(8):485-8. PubMed ID: 16845646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder.
    Kagawa S; Mihara K; Suzuki T; Nagai G; Nakamura A; Nemoto K; Kondo T
    Neuropsychobiology; 2017; 75(3):145-150. PubMed ID: 29332095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidepressant discontinuation syndrome.
    Antai-Otong D
    Perspect Psychiatr Care; 2003; 39(3):127-8. PubMed ID: 14606234
    [No Abstract]   [Full Text] [Related]  

  • 13. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder.
    Calabrese JR; Bowden CL; Sachs G; Yatham LN; Behnke K; Mehtonen OP; Montgomery P; Ascher J; Paska W; Earl N; DeVeaugh-Geiss J;
    J Clin Psychiatry; 2003 Sep; 64(9):1013-24. PubMed ID: 14628976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lamotrigine augmentation strategy for patients with treatment-resistant depression.
    Gutierrez RL; McKercher RM; Galea J; Jamison KL
    CNS Spectr; 2005 Oct; 10(10):800-5. PubMed ID: 16400242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study.
    Schindler F; Anghelescu IG
    Int Clin Psychopharmacol; 2007 May; 22(3):179-82. PubMed ID: 17414745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial.
    van der Loos ML; Mulder PG; Hartong EG; Blom MB; Vergouwen AC; de Keyzer HJ; Notten PJ; Luteijn ML; Timmermans MA; Vieta E; Nolen WA;
    J Clin Psychiatry; 2009 Feb; 70(2):223-31. PubMed ID: 19200421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
    Solmi M; Veronese N; Zaninotto L; van der Loos ML; Gao K; Schaffer A; Reis C; Normann C; Anghelescu IG; Correll CU
    CNS Spectr; 2016 Oct; 21(5):403-418. PubMed ID: 27686028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open study of lamotrigine in refractory bipolar depression.
    Kusumakar V; Yatham LN
    Psychiatry Res; 1997 Sep; 72(2):145-8. PubMed ID: 9335206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design.
    van der Loos ML; Mulder P; Hartong EG; Blom MB; Vergouwen AC; van Noorden MS; Timmermans MA; Vieta E; Nolen WA;
    Bipolar Disord; 2011 Feb; 13(1):111-7. PubMed ID: 21320258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
    Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.